Lupus Erythematosus accounts for 8.2% share of global Immunology clinical trial activity in 2020 - Clinical Trials Arena
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Lupus Erythematosus accounts for 8.2% share of global Immunology clinical trial activity in 2020

12 Oct 2021

Lupus Erythematosus accounted for an 8.2% share of the global clinical trials within the Immunology therapy area in 2020, registering an increase of 1.6% when compared with the last ten-year average of 6.6% share, according to GlobalData.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Industry sponsored trials outnumber non-industry sponsored trials for Lupus Erythematosus

Industry sponsored trials held a 68.9% share of all the clinical trials for Lupus Erythematosus indication in 2020, registering an increase of 15.8% when compared with the ten-year average of 53.1%. Non-industry sponsored trials accounted for a 31.1% share in 2020, marking a decrease of 15.8% over the ten-year average of 46.9%.


  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Top regions of industry sponsored Lupus Erythematosus trials

Europe was the top region for industry sponsored Lupus Erythematosus trials, accounting for a 50.0% share in 2020, when compared with the five-year average of 43.5% and ten-year average of 46.1%.

North America was at the second position with a 50.0% share in 2020, over the five-year average of 61.5% and ten-year average of 64.0%, followed by Asia-Pacific with a 40.5% share in 2020, as against five-year and ten-year averages of 41.7% and 42.6% respectively.

South and Central America stood fourth with a 19.0% share in 2020, compared with the five-year average of 19.4% and ten-year average of 23.1%, followed by Middle East and Africa with a 7.1% share in 2020, over five-year and ten-year averages of 11.7% and 14.4% respectively.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

The US was the top country for industry sponsored Lupus Erythematosus trials, accounting for a 47.6% share in 2020, as against the five-year average of 60.4% and ten-year average of 62.5%.

Germany held a 33.3% share in 2020, over the five-year average of 21.5% and ten-year average of 22.9%, followed by Spain with a 26.2% share in 2020, compared with the five-year and ten-year averages of 17.6% and 20.3% respectively.

The UK held a 21.4% share in 2020, as against the five-year average of 12.8% and ten-year average of 15.8%.

Poland held a 21.4% share in 2020, over the five-year and ten-year averages of 19.5% and 20.1% respectively.

Top regions of non-industry sponsored Lupus Erythematosus trials

Asia-Pacific was the top region for non-industry sponsored Lupus Erythematosus trials, accounting for a 52.4% share in 2020 when compared with the five-year average of 57.7% and ten-year average of 51.9%.

North America was at the second position with a 19.0% share in 2020, over the five-year and ten-year averages of 21.1% and 22.4% respectively, followed by Middle East and Africa with a 14.3% share in 2020, as against the five-year average of 6.3% and ten-year average of 6.4%.

Europe stood at the fourth position with a 9.5% share in 2020, compared with the five-year average of 13.7% and ten-year average of 17.1%, followed by South and Central America with a 4.8% share in 2020, over the five-year and ten-year averages of 6.2% and 5.5% respectively.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

China was the top country for non-industry sponsored Lupus Erythematosus trials, accounting for a 38.1% share in 2020, as against the five-year average of 33.1% and ten-year average of 24.7%.

The US held a 19.0% share in 2020, over the five-year average of 19.0% and ten-year average of 21.3%, followed by Iran with a 14.3% share, compared with the five-year and ten-year averages of 3.0% and 4.0% respectively.

France held a 4.8% share in 2020, as against the five-year average of 5.5% and ten-year average of 6.3%.

Germany held a 4.8% share in 2020, over the five-year average of 1.3% and ten-year average of 2.6%.

Phase I trials lead industry sponsored clinical trials for Lupus Erythematosus in 2020

Phase I trials held a 56.9% share of industry sponsored clinical trials for Lupus Erythematosus in 2020, over the five-year average of 56.1% and ten-year average of 50.1%.

Phase II trials held a 21.6% share in 2020, as against the five-year average of 30.4% and ten-year average of 31.0%. Phase III trials held a 17.6% share in 2020, compared with the five-year and ten-year averages of 9.3% and 12.2% respectively.

Phase IV trials held a 3.9% share in 2020, over the five-year average of 4.2% and ten-year average of 6.8%.

Phase IV trials lead non-industry sponsored clinical trials for Lupus Erythematosus in 2020

Phase IV trials held a 43.5% share of non-industry sponsored clinical trials for Lupus Erythematosus in 2020, over the five-year average of 22.3% and ten-year average of 26.4%.

Phase I trials held a 26.1% share in 2020, as against the five-year average of 13.5% and ten-year average of 9.7%. Phase II trials held a 17.4% share, compared with the five-year and ten-year averages of 58.4% and 54.4% respectively.

Phase III trials held a 13.0% share in 2020, over the five-year average of 5.8% and ten-year average of 9.5%.

Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.